{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05064319",
            "orgStudyIdInfo": {
                "id": "00112593"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01DA054275",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01DA054275"
                }
            ],
            "organization": {
                "fullName": "Medical University of South Carolina",
                "class": "OTHER"
            },
            "briefTitle": "Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders",
            "officialTitle": "Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders: A Randomized, Double-blind, Placebo-controlled, Parallel-group, MRI Study",
            "therapeuticArea": [
                "Mental Health",
                "Other"
            ],
            "study": "gabapentin-for-restoring-gaba-glutamate-homeostasis-in-co-occurring-bipolar-and-cannabis-use-disorders"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-02-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-09-22",
            "studyFirstSubmitQcDate": "2021-09-22",
            "studyFirstPostDateStruct": {
                "date": "2021-10-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "James J. Prisciandaro",
                "investigatorTitle": "Associate Professor",
                "investigatorAffiliation": "Medical University of South Carolina"
            },
            "leadSponsor": {
                "name": "Medical University of South Carolina",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This research study evaluates the effects of an FDA-approved medication Gabapentin in individuals with Bipolar Disorder who smoke marijuana. Participants in the study will will be assigned to take either Gabapentin or a matched placebo. Study medication will be taken for 17 days. There will be 5 study visits, with 2 MRI brain imaging scans completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication."
        },
        "conditionsModule": {
            "conditions": [
                "Bipolar Disorder",
                "Cannabis Use",
                "Schizoaffective Disorder, Bipolar Type",
                "Bipolar I Disorder",
                "Bipolar II Disorder",
                "Cannabis Use Disorder, Mild",
                "Cannabis Use Disorder, Moderate",
                "Cannabis Use Disorder, Severe"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 68,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group A - Gabapentin",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Gabapentin"
                    ]
                },
                {
                    "label": "Group B - Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Gabapentin",
                    "description": "After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive gabapentin 2-3 times a day for a total of 17 days.",
                    "armGroupLabels": [
                        "Group A - Gabapentin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.",
                    "armGroupLabels": [
                        "Group B - Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in prefrontal GABA concentrations through Proton Magnetic Resonance Spectroscopy",
                    "description": "Concentrations of GABA, normalized to water and corrected for CSF%, in dorsal anterior cingulate measured via Proton Magnetic Resonance Spectroscopy.",
                    "timeFrame": "Baseline to end of treatment, approximately 17 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Ages 18-65 years\n2. Meet DSM-5 criteria for moderate or severe cannabis use disorder (CUD; within the past 3 months), provide a positive urine cannabinoid screen at baseline, and identify cannabis as the primary substance of abuse\n3. Meet DSM-5 criteria for bipolar I or II disorder (BD) or Schizoaffective Disorder, Bipolar Type\n4. Able to provide informed consent and read, understand, and accurately complete assessment instruments\n5. Willing to commit to medication treatment and follow-up assessments\n6. Prescribed daily use of at least one mood stabilizing medication (i.e., lithium, divalproex sodium, lamotrigine, carbamazepine, 2nd generation antipsychotic)\n\nExclusion Criteria:\n\n1. A primary psychiatric diagnosis other than BD (e.g., Schizophrenia)\n2. Meet DSM-5 criteria for moderate or severe substance use disorder (other than cannabis or tobacco) within the past 60 days\n3. Any uncontrolled neurological condition (e.g., epilepsy) that could confound the results of the study\n4. Any history of brain injury with loss of consciousness greater than 5 minutes\n5. Any history of mental retardation, dementia, or recent electroconvulsive therapy (in the past 3 months)\n6. Any uncontrolled medical condition that may adversely affect the conduct of the study or jeopardize the safety of the participant\n7. Hepatocellular disease as indicated by plasma levels of liver transaminases (aspartate transaminase, alanine transaminase) greater than 3 times the normal range\n8. Renal insufficiency as indicated by plasma levels of creatinine greater than 2 times the normal range\n9. Concomitant use of medications that could interfere with glutamatergic/GABAergic transmission (e.g., benzodiazepines, ceftriaxone, riluzole, memantine, ketamine, topiramate, vigabatrin), due to potential confounding effects\n10. Concomitant use of opioid medications, benzodiazepines, barbiturates, chloral hydrate, sodium oxybate, or any other medication deemed to be hazardous if taken with gabapentin\n11. Azelastine, orphenadrine, oxomemazine, paraldehyde, and thalidomide are generally contraindicated in patients taking gabapentin; as such, individuals taking these medications will be excluded\n12. Women of childbearing potential who are pregnant, lactating, or refuse adequate forms of contraception\n13. Current suicidal or homicidal risk\n14. Baseline scores greater than 35 on the Montgomery-Asberg Depression Rating Scale or greater than 25 on the Young Mania Rating Scale\n15. Has taken gabapentin in the last month or experienced adverse effects/allergic reaction (e.g., angioedema) from it at any time\n16. Significant claustrophobia and/or past negative experiences with MRI\n17. Presence of non-MRI safe materials in the body (e.g., ferrous metal implants, pacemaker)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sara Hix",
                    "role": "CONTACT",
                    "phone": "843-792-7500",
                    "email": "hixs@musc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "James J Prisciandaro, PhD",
                    "affiliation": "Medical University of South Carolina",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Medical University Of South Carolina",
                    "status": "RECRUITING",
                    "city": "Charleston",
                    "state": "South Carolina",
                    "zip": "29425",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sara Hix",
                            "role": "CONTACT",
                            "phone": "843-792-0572",
                            "email": "hixs@musc.edu"
                        },
                        {
                            "name": "James J Prisciandaro, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.77657,
                        "lon": -79.93092
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002189",
                    "term": "Marijuana Abuse"
                },
                {
                    "id": "D000001714",
                    "term": "Bipolar Disorder"
                },
                {
                    "id": "D000011618",
                    "term": "Psychotic Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000068105",
                    "term": "Bipolar and Related Disorders"
                },
                {
                    "id": "D000019964",
                    "term": "Mood Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000019967",
                    "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5449",
                    "name": "Marijuana Abuse",
                    "asFound": "Cannabis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4996",
                    "name": "Bipolar Disorder",
                    "asFound": "Bipolar Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "asFound": "Schizoaffective Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M226",
                    "name": "Bipolar and Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21835",
                    "name": "Mood Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M15376",
                    "name": "Schizophrenia",
                    "relevance": "LOW"
                },
                {
                    "id": "M21838",
                    "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077206",
                    "term": "Gabapentin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000927",
                    "term": "Anticonvulsants"
                },
                {
                    "id": "D000014151",
                    "term": "Anti-Anxiety Agents"
                },
                {
                    "id": "D000014149",
                    "term": "Tranquilizing Agents"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000018691",
                    "term": "Excitatory Amino Acid Antagonists"
                },
                {
                    "id": "D000018683",
                    "term": "Excitatory Amino Acid Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018692",
                    "term": "Antimanic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1694",
                    "name": "Gabapentin",
                    "asFound": "Guidance",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4246",
                    "name": "Anticonvulsants",
                    "relevance": "LOW"
                },
                {
                    "id": "M16905",
                    "name": "Anti-Anxiety Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M20771",
                    "name": "Excitatory Amino Acid Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "T5",
                    "name": "Glutamic Acid",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "AntiConv",
                    "name": "Anticonvulsants"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}